Literature DB >> 29083949

Lipid mediators in the regulation of endothelial barriers.

Pratap Karki1, Konstantin G Birukov2.   

Abstract

Lipid mediators play a critical role in the development and resolution of vascular endothelial barrier dysfunction caused by various pathologic interventions. The accumulation of excess lipids directly impairs endothelial cell (EC) barrier function that is known to contribute to the development of atherosclerosis and metabolic disorders such as obesity and diabetes as well as chronic inflammation in the vascular endothelium. Certain products of phospholipid oxidation (OxPL) such as fragmented phospholipids generated during oxidative and nitrosative stress show pro-inflammatory potential and cause endothelial barrier dysfunction. In turn, other OxPL products enhance basal EC barrier and exhibit potent barrier-protective effects in pathologic settings of acute vascular leak caused by pro-inflammatory mediators, barrier disruptive agonists and pathologic mechanical stimulation. These beneficial effects were further confirmed in rodent models of lung injury and inflammation. The bioactive oxidized lipid molecules may serve as important therapeutic prototype molecules for future treatment of acute lung injury syndromes associated with endothelial barrier dysfunction and inflammation. This review will summarize recent studies of biological effects exhibited by various groups of lipid mediators with a focus on the role of oxidized phospholipids in control of vascular endothelial barrier, agonist induced EC permeability, inflammation, and barrier recovery related to clinical settings of acute lung injury and inflammatory vascular leak.

Entities:  

Keywords:  EP4 receptor; OxPAPC; endothelial barrier; lipoxin; oxidized phospholipids; prostaglandins; sphingosine-1-phosphate

Mesh:

Substances:

Year:  2017        PMID: 29083949      PMCID: PMC5823549          DOI: 10.1080/21688370.2017.1385573

Source DB:  PubMed          Journal:  Tissue Barriers        ISSN: 2168-8362


  145 in total

1.  Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists.

Authors:  Suzanne Mandala; Richard Hajdu; James Bergstrom; Elizabeth Quackenbush; Jenny Xie; James Milligan; Rosemary Thornton; Gan-Ju Shei; Deborah Card; CarolAnn Keohane; Mark Rosenbach; Jeffrey Hale; Christopher L Lynch; Kathleen Rupprecht; William Parsons; Hugh Rosen
Journal:  Science       Date:  2002-03-28       Impact factor: 47.728

Review 2.  Cell signalling through thromboxane A2 receptors.

Authors:  Jin-Sheng Huang; Santosh K Ramamurthy; Xin Lin; Guy C Le Breton
Journal:  Cell Signal       Date:  2004-05       Impact factor: 4.315

3.  Identification of inflammatory gene modules based on variations of human endothelial cell responses to oxidized lipids.

Authors:  Peter S Gargalovic; Minori Imura; Bin Zhang; Nima M Gharavi; Michael J Clark; Joanne Pagnon; Wen-Pin Yang; Aiqing He; Amy Truong; Shilpa Patel; Stanley F Nelson; Steve Horvath; Judith A Berliner; Todd G Kirchgessner; Aldons J Lusis
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-15       Impact factor: 11.205

4.  Oxidized phospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK/EGR-1 and Ca(++)/NFAT.

Authors:  Valery N Bochkov; Diana Mechtcheriakova; Marcus Lucerna; Joakim Huber; Roland Malli; Wolfgang F Graier; Erhard Hofer; Bernd R Binder; Norbert Leitinger
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

5.  Afadin controls p120-catenin-ZO-1 interactions leading to endothelial barrier enhancement by oxidized phospholipids.

Authors:  Anna A Birukova; Panfeng Fu; Tinghuai Wu; Oleksii Dubrovskyi; Nicolene Sarich; Valery Poroyko; Konstantin G Birukov
Journal:  J Cell Physiol       Date:  2012-05       Impact factor: 6.384

6.  Postinjury thromboxane receptor blockade ameliorates acute lung injury.

Authors:  C D Goff; R S Corbin; S D Theiss; H F Frierson; G A Cephas; C G Tribble; I L Kron; J S Young
Journal:  Ann Thorac Surg       Date:  1997-09       Impact factor: 4.330

7.  Leukocyte extravasation and vascular permeability are each controlled in vivo by different tyrosine residues of VE-cadherin.

Authors:  Florian Wessel; Mark Winderlich; Maren Holm; Maike Frye; Ronmy Rivera-Galdos; Matthias Vockel; Ruth Linnepe; Ute Ipe; Anika Stadtmann; Alexander Zarbock; Astrid F Nottebaum; Dietmar Vestweber
Journal:  Nat Immunol       Date:  2014-02-09       Impact factor: 25.606

8.  Increased lipid peroxidation in patients with pulmonary hypertension.

Authors:  J L Cracowski; C Cracowski; G Bessard; J L Pepin; J Bessard; C Schwebel; F Stanke-Labesque; C Pison
Journal:  Am J Respir Crit Care Med       Date:  2001-09-15       Impact factor: 21.405

Review 9.  Anti-inflammatory properties of lipid oxidation products.

Authors:  Valery N Bochkov; Norbert Leitinger
Journal:  J Mol Med (Berl)       Date:  2003-09-06       Impact factor: 4.599

10.  Oxidized phospholipids reduce ventilator-induced vascular leak and inflammation in vivo.

Authors:  Stephanie Nonas; Anna A Birukova; Panfeng Fu; Jungjie Xing; Santipongse Chatchavalvanich; Valery N Bochkov; Norbert Leitinger; Joe G N Garcia; Konstantin G Birukov
Journal:  Crit Care       Date:  2008-01-24       Impact factor: 9.097

View more
  16 in total

1.  Pretransplant Systemic Lipidomic Profiles in Allogeneic Stem Cell Transplant Recipients.

Authors:  Kimberley Joanne Hatfield; Øystein Bruserud; Håkon Reikvam
Journal:  Cancers (Basel)       Date:  2022-06-13       Impact factor: 6.575

Review 2.  S1P and plasmalogen derived fatty aldehydes in cellular signaling and functions.

Authors:  David L Ebenezer; Panfeng Fu; Ramaswamy Ramchandran; Alison W Ha; Vijay Putherickal; Tara Sudhadevi; Anantha Harijith; Fabian Schumacher; Burkhard Kleuser; Viswanathan Natarajan
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2020-03-12       Impact factor: 4.698

Review 3.  Oxidized Phospholipids in Healthy and Diseased Lung Endothelium.

Authors:  Pratap Karki; Konstantin G Birukov
Journal:  Cells       Date:  2020-04-15       Impact factor: 6.600

4.  Role of truncated oxidized phospholipids in acute endothelial barrier dysfunction caused by particulate matter.

Authors:  Pratap Karki; Angelo Meliton; Alok Shah; Yufeng Tian; Tomomi Ohmura; Nicolene Sarich; Anna A Birukova; Konstantin G Birukov
Journal:  PLoS One       Date:  2018-11-12       Impact factor: 3.240

Review 5.  Contribution of Angiogenesis to Inflammation and Cancer.

Authors:  Dolores Aguilar-Cazares; Rodolfo Chavez-Dominguez; Angeles Carlos-Reyes; César Lopez-Camarillo; Olga N Hernadez de la Cruz; Jose S Lopez-Gonzalez
Journal:  Front Oncol       Date:  2019-12-12       Impact factor: 6.244

6.  Uncovering emergent phenotypes in endothelial cells by clustering of surrogates of cardiovascular risk factors.

Authors:  Iguaracy Pinheiro-de-Sousa; Miriam H Fonseca-Alaniz; Samantha K Teixeira; Mariliza V Rodrigues; Jose E Krieger
Journal:  Sci Rep       Date:  2022-01-25       Impact factor: 4.379

Review 7.  Visualizing cancer extravasation: from mechanistic studies to drug development.

Authors:  Xiao Cheng; Ke Cheng
Journal:  Cancer Metastasis Rev       Date:  2020-11-06       Impact factor: 9.264

8.  Endothelial Immunity Trained by Coronavirus Infections, DAMP Stimulations and Regulated by Anti-Oxidant NRF2 May Contribute to Inflammations, Myelopoiesis, COVID-19 Cytokine Storms and Thromboembolism.

Authors:  Ying Shao; Jason Saredy; Keman Xu; Yu Sun; Fatma Saaoud; Charles Drummer; Yifan Lu; Jin J Luo; Jahaira Lopez-Pastrana; Eric T Choi; Xiaohua Jiang; Hong Wang; Xiaofeng Yang
Journal:  Front Immunol       Date:  2021-06-25       Impact factor: 7.561

Review 9.  Nanomedicine for Gene Delivery for the Treatment of Cardiovascular Diseases.

Authors:  Cen Yan; Xiao-Jiang Quan; Ying-Mei Feng
Journal:  Curr Gene Ther       Date:  2019       Impact factor: 4.391

Review 10.  The Gut-Lung Axis in Systemic Inflammation. Role of Mesenteric Lymph as a Conduit.

Authors:  Yonggang Ma; Xiaoyuan Yang; Victor Chatterjee; Mack H Wu; Sarah Y Yuan
Journal:  Am J Respir Cell Mol Biol       Date:  2021-01       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.